On February 24, 2026 Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, reported financial results for the quarter and year ended December 31, 2025.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Fourth quarter revenue of $367.2 million, up 83.0% year-over-year with 33.5% organic growth (excluding Ambry)
Diagnostics revenue of $266.9 million in the fourth quarter, representing 121.6% growth year-over-year, driven by Oncology volume growth of 29% and Hereditary volume growth of 23%
MRD volume was ~4,700 tests in the fourth quarter, up 56% quarter-over-quarter
Data and Applications revenue of $100.4 million in the fourth quarter, representing 25.1% year-over-year growth, with Insights (data licensing) growing 69.5%, excluding the impact of the AstraZeneca warrant in Q4 of 2024
Ended the year with over $1.1 billion in Total Remaining Contract Value and 126% Net Revenue Retention
$759.7 million in cash and marketable securities as of December 31, 2025
Revenue guidance of $1.59 billion for 2026 and expect full year 2026 Adjusted EBITDA of approximately $65 million
"In 2025, Tempus continued to set the standard for what it means to be a technology company operating in the healthcare space," said Eric Lefkofsky, Founder and CEO of Tempus. "The strength of our unit growth in diagnostics along with the accelerating growth of our data business is proof that we are unique in this space. As the network effects from our investments in AI continue to compound, we expect to not only drive significant growth over the next several years, but to also enhance the lives of millions of patients around the world."
Fourth Quarter Summary Results:
Revenue increased 83.0% year-over-year to $367.2 million in the fourth quarter.
Diagnostics generated $266.9 million of revenue in the quarter, representing 121.6% year-over-year growth, with Oncology volume growth of 29% year-over-year and Hereditary volume growth of 23%.
Data and Applications generated $100.4 million of revenue in the quarter, representing 25.1% year-over-year growth, with Insights growing 69.5% (excluding the impact of the AstraZeneca warrant in Q4 of 2024).
Gross profit increased 94.7% year-over-year to $237.7 million, led by strong performance in Diagnostics.
Net loss was ($54.2 million), which included $48.7 million of stock compensation expense and related employer payroll taxes in the fourth quarter, compared to a net loss of ($13.0 million) in the fourth quarter of 2024 and a net loss of ($80.0 million) in the third quarter of 2025.
Adjusted EBITDA improved to $12.9 million in the fourth quarter, compared to ($7.8 million) in the fourth quarter of 2024 and $1.5 million in the third quarter of 2025.
Full Year 2025 Summary Results:
Revenue increased 83.4% year-over-year to $1.3 billion in 2025.
Diagnostics generated $955.4 million of revenue, or 111.5% year-over-year growth, with Oncology volume growth of 26% year-over-year and Hereditary volume growth of 29%.
Data and Applications generated $316.4 million of revenue, accelerating 30.9% year-over-year, with Insights growth of 38.0%.
Ended the year with over $1.1 billion in remaining Total Contract Value and Net Revenue Retention of 126%.
Gross profit increased to $797.9 million, representing 109.4% growth year-over-year.
Net loss was ($245.0 million), which included $136.3 million of stock compensation expense and related employer payroll taxes.
Adjusted EBITDA improved $97.3 million year-over-year to ($7.4 million), even after the acquisitions of Paige AI and OneOme.
Recent Operational Highlights
Launched Paige Predict, an AI-powered digital pathology suite that analyzes standard H&E slides to predict 123 biomarkers across 16 cancer types, helping clinicians make informed testing decisions even when tissue samples are limited, which improves Tempus’ ability to render insights across its genomic tests.
Announced results from a new study demonstrating that Tempus’ AI-driven Immune Profile Score (IPS) test more accurately predicts immunotherapy outcomes across various cancers than conventional biomarkers, identifying potential responders—including 13% of colorectal and 17% of rare cancer patients—who would otherwise be overlooked by standard testing.
Entered a multi-year strategic collaboration with NYU Langone Health, centered on a prospective observational study that uses serial molecular profiling to track cancer evolution and treatment resistance, with the goal of developing AI-powered diagnostic tools and personalized therapies.
Selected by Northwestern Medicine to expand genomic testing access to oncology patients across the health system, leveraging Tempus’ full suite of DNA, RNA, liquid biopsy, and MRD tests to enable more personalized cancer care and clinical trial design.
Fourth Quarter and Full Year 2025 Financial Results
Three Months Ended
December 31, 2025
Year Ended
December 31, 2025
(in thousands, except percentages and per share amounts)
(unaudited)
Revenue
$
367,211
$
1,271,789
Year-over-year growth
83.0
%
83.4
%
Gross profit
$
237,713
$
797,897
Loss from operations
$
(61,413
)
$
(252,872
)
Net loss
$
(54,166
)
$
(245,028
)
Adjusted EBITDA
$
12,893
$
(7,385
)
Net loss per share attributable to common shareholders, basic and diluted
$
(0.30
)
$
(1.41
)
Non-GAAP net loss per share
$
(0.04
)
$
(0.61
)
Financial Outlook and Guidance
Tempus is providing full year 2026 revenue guidance of approximately $1.59 billion, which represents ~25% annual growth. We expect 2026 Adjusted EBITDA to be ~$65 million.
For additional information on the quarter, including a letter from our CEO and CFO, please visit our investor relations site at investors.tempus.com.
Webcast and Conference Call Information
A conference call and webcast will begin today, February 24, 2026 after market close at 4:30 p.m. Eastern Time. Interested parties may access details at:
Conference ID: 4652845
United States – New York: (646) 307-1963
USA & Canada – Toll-Free: (800) 715-9871
Live webcast: View Source
The webcast may be accessed on the company’s investor relations website at investors.tempus.com. For those unable to listen to the live webcast, a recording will be made available on the company’s website after the event and will be accessible for one year. Visit the investor relations website to find the company’s latest deck, and commentary on the quarter by Eric Lefkofsky, Founder and CEO and Jim Rogers, CFO, which will be discussed on the conference call and webcast.
(Press release, Tempus, FEB 24, 2026, View Source [SID1234662951])